HC Wainwright Comments on iBio's Q1 Earnings (NASDAQ:IBIO)

Key Points

• HC Wainwright maintained a “Strong-Buy” rating on iBio and forecasts a Q1 2027 loss of $0.05 per share, with a projected FY2027 loss of $0.30 per share.
• Analysts expect iBio to remain unprofitable through 2030, including projected losses of $0.62 per share in FY2028, $0.51 in FY2029 and $0.57 in FY2030.
• MarketBeat reports a consensus “Buy” rating and $5.29 price target, while iBio recently reported a quarterly loss of $0.04 per share—better than the $0.07 consensus estimate. Shares opened at $1.28 and remain well below their 52-week high of $3.82.

iBio, Inc. (NASDAQ:IBIO - Free Report) - Equities researchers at HC Wainwright issued their Q1 2027 EPS estimates for iBio in a research report issued on Thursday, September 17th. HC Wainwright analyst A. Ghosh forecasts that the company will earn ($0.05) per share for the quarter. HC Wainwright has a "Strong-Buy" rating on the stock. The consensus estimate for iBio's current full-year earnings is ($0.39) per share. HC Wainwright also issued estimates for iBio's Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.10) EPS, FY2027 earnings at ($0.30) EPS, Q1 2028 earnings at ($0.09) EPS, Q2 2028 earnings at ($0.12) EPS, Q3 2028 earnings at ($0.16) EPS, Q4 2028 earnings at ($0.25) EPS, FY2028 earnings at ($0.62) EPS, FY2029 earnings at ($0.51) EPS and FY2030 earnings at ($0.57) EPS.

Several other equities research analysts also recently commented on the company. Raymond James Financial began coverage on iBio in a report on Monday, June 8th. They set an "outperform" rating and a $5.00 target price for the company. B. Riley Financial initiated coverage on iBio in a research note on Friday, June 5th. They issued a "buy" rating and a $6.00 price target on the stock. Wall Street Zen downgraded iBio from a "hold" rating to a "sell" rating in a report on Sunday, September 13th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of iBio in a research note on Wednesday, June 24th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $5.00 price objective on shares of iBio in a research note on Thursday, July 2nd. Four research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $5.29.

iBio Price Performance

IBIO opened at $1.28 on Monday. The firm has a market cap of $82.32 million, a PE ratio of -3.76 and a beta of 1.29. The business has a fifty day simple moving average of $1.37 and a 200-day simple moving average of $1.71. iBio has a fifty-two week low of $0.77 and a fifty-two week high of $3.82.

iBio (NASDAQ:IBIO - Get Free Report) last posted its quarterly earnings results on Friday, August 28th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.03.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of IBIO. Squarepoint Ops LLC purchased a new stake in iBio in the 2nd quarter worth about $873,000. Headlands Technologies LLC grew its stake in iBio by 333.0% during the 2nd quarter. Headlands Technologies LLC now owns 47,413 shares of the company's stock valued at $83,000 after acquiring an additional 36,463 shares in the last quarter. Bank of America Corp DE grew its stake in iBio by 150.8% during the 1st quarter. Bank of America Corp DE now owns 290,413 shares of the company's stock valued at $552,000 after acquiring an additional 174,620 shares in the last quarter. ADAR1 Capital Management LLC increased its holdings in shares of iBio by 15.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 469,878 shares of the company's stock valued at $893,000 after purchasing an additional 64,347 shares during the period. Finally, Affinity Asset Advisors LLC increased its holdings in shares of iBio by 51.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,107,200 shares of the company's stock valued at $5,904,000 after purchasing an additional 1,050,000 shares during the period. Hedge funds and other institutional investors own 7.90% of the company's stock.

iBio News Summary

Here are the key news stories impacting iBio this week:

• Positive Sentiment: HC Wainwright upgraded iBio and reiterated its “Strong-Buy” view, providing a favorable analyst catalyst for IBIO. iBio Upgraded at HC Wainwright
• Positive Sentiment: The analyst’s 2027 full-year EPS forecast of -$0.30 is less negative than the company’s current-year consensus estimate of -$0.41, suggesting expectations for improved results over the near term.
• Neutral Sentiment: HC Wainwright issued detailed quarterly and annual forecasts through fiscal 2030, including EPS estimates of -$0.62 for 2028, -$0.51 for 2029, and -$0.57 for 2030. These projections give investors a longer-term framework but do not indicate anticipated profitability.
• Negative Sentiment: iBio is still expected to report losses in every forecast period, with projected 2028 quarterly losses widening from -$0.09 to -$0.25. Continued negative earnings and the absence of a clear path to profitability remain risks for shareholders.

About iBio

iBio, Inc is a biotechnology company focused on discovering and developing next-generation antibody therapeutics. The company uses artificial intelligence, machine learning and computational biology to identify antibody candidates and optimize their properties for potential use in cancer, autoimmune, inflammatory and fibrotic diseases.

iBio's technology platform is based in part on the antibody-discovery capabilities obtained through its acquisition of RubrYc Therapeutics. The platform is designed to support target selection, antibody generation and optimization, with an emphasis on identifying antibodies that bind specific disease-related epitopes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.